Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Ifosfamide Pregnancy and Breastfeeding Warnings

Ifosfamide is also known as: Ifex

Medically reviewed on Oct 2, 2018

Ifosfamide Pregnancy Warnings

Ifosfamide has been assigned to pregnancy category D by the FDA. Animal studies have revealed evidence of embryotoxicity, fetotoxicity, and teratogenicity at doses 5.0% to 7.5% of the human dose on a per m2 basis. This drug can cause gene mutations and chromosomal damage in vivo. Human data have revealed evidence of fetotoxicity. If ifosfamide is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. In general, the use of ifosfamide during pregnancy is considered contraindicated.

See references

Ifosfamide Breastfeeding Warnings

Ifosfamide is excreted into human milk. Because of the potential for serious adverse events and the tumorigenicity shown for ifosfamide in animal studies, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the nursing mother.

See references

References for pregnancy information

  1. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.

References for breastfeeding information

  1. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.